Corteva (NYSE:CTVA) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says

Corteva (NYSE:CTVA) had its target price lifted by Deutsche Bank Aktiengesellschaft from $85.00 to $90.00 in a research note issued on Thursday,MarketScreener reports. The brokerage presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 23.49% from the stock’s current price.

CTVA has been the topic of several other research reports. UBS Group reduced their price objective on shares of Corteva from $85.00 to $81.00 and set a “buy” rating for the company in a research note on Thursday, October 30th. Royal Bank Of Canada lifted their target price on shares of Corteva from $80.00 to $89.00 and gave the company an “outperform” rating in a research report on Thursday. Argus upgraded shares of Corteva to a “strong-buy” rating in a research report on Friday, January 16th. Mizuho boosted their price objective on shares of Corteva from $78.00 to $80.00 and gave the company an “outperform” rating in a report on Friday, January 16th. Finally, Oppenheimer set a $86.00 price objective on shares of Corteva in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Corteva presently has an average rating of “Moderate Buy” and an average target price of $82.37.

Corteva Stock Up 0.6%

CTVA stock opened at $72.88 on Thursday. The company has a fifty day moving average of $68.72 and a 200-day moving average of $68.43. The stock has a market capitalization of $49.25 billion, a PE ratio of 46.10, a price-to-earnings-growth ratio of 1.86 and a beta of 0.75. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.07 and a current ratio of 1.43. Corteva has a one year low of $53.40 and a one year high of $77.41.

Corteva (NYSE:CTVA) last released its earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.22. The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The firm’s quarterly revenue was down 1.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.32 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, analysts expect that Corteva will post 2.96 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Corteva by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 80,536,951 shares of the company’s stock worth $5,398,392,000 after purchasing an additional 317,538 shares during the period. State Street Corp boosted its stake in shares of Corteva by 3.6% in the third quarter. State Street Corp now owns 35,280,805 shares of the company’s stock valued at $2,386,041,000 after purchasing an additional 1,230,074 shares during the period. Franklin Resources Inc. raised its holdings in Corteva by 5.9% during the third quarter. Franklin Resources Inc. now owns 18,731,627 shares of the company’s stock worth $1,266,820,000 after purchasing an additional 1,051,389 shares in the last quarter. Geode Capital Management LLC raised its position in Corteva by 1.4% in the second quarter. Geode Capital Management LLC now owns 18,047,263 shares of the company’s stock worth $1,339,651,000 after acquiring an additional 251,693 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Corteva by 1.8% during the third quarter. Northern Trust Corp now owns 11,169,284 shares of the company’s stock valued at $755,379,000 after buying an additional 194,728 shares during the period. Institutional investors own 81.54% of the company’s stock.

More Corteva News

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: RBC raised its price target to $89 and kept an “outperform” rating — a bullish analyst signal that implies ~23% upside from the recent price. RBC raises price target
• Positive Sentiment: Consensus broker view listed as “Moderate Buy,” reflecting broad analyst support that can help underpin the stock. Consensus Moderate Buy
• Neutral Sentiment: Coverage piece argues the bull case for Corteva could shift after developments in a Bayer settlement and licensing arrangements — potential structural implications but outcome and timing remain uncertain. Bull case and Bayer/licensing
• Neutral Sentiment: Report noting conflicting analyst views — some upgrading targets, others trimming ratings — highlighting divergence in expectations for growth and valuation. Conflicting analyst sentiments
• Neutral Sentiment: CFO/management commentary and the earnings presentation highlighted record free cash flow and strategic execution, positive fundamentals that may temper the headline revenue miss. Earnings call highlights
• Negative Sentiment: Q4 revenue missed estimates due to seasonal timing shifts and lower crop-protection and seed demand; the miss caused shares to fall in after-hours trading. This direct earnings disappointment is the primary near-term negative catalyst. Revenue miss and seasonality
• Negative Sentiment: JPMorgan downgraded Corteva from “overweight” to “neutral,” citing valuation and limited near-term upside despite a slightly higher $77 target — another headwind to sentiment. JPMorgan downgrade

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.